You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Expression of cancer testis antigens and its correlation with clinicopathological parameters in hepatocellular carcinoma
  1. Meng Wang1,2,
  2. Xin-feng Chen2,6,
  3. Zhi-qin Li3,
  4. Zhen Zhang2,6,
  5. Dong-li Yue2,6,
  6. Yan-hong Liu1,
  7. Dong Jiang1,
  8. Yu-ling Sun4,
  9. Yong-fu Zhao4,
  10. Shu-huan Wu3,
  11. Jian-sheng Li1 and
  12. Yi Zhang2,5,6
  1. Aff1 grid.412633.1Department of Gastroenterologythe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  2. Aff2 grid.412633.1Biotherapy Centerthe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  3. Aff3 grid.412633.1Department of Infectious Diseasesthe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  4. Aff4 grid.412633.1Department of Hepatobiliary Surgerythe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  5. Aff5 grid.412633.1Department of Bioengineeringthe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  6. Aff6 grid.412633.1Department of Oncologythe First Affiliated Hospital of Zhengzhou University Zhengzhou China

https://doi.org/10.1186/2051-1426-1-S1-P250

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Many therapies such as surgery, chemical or physical approaches have been used for treatment of HCC; however, the outcome is still poor. Cancer immunotherapy is considered to be one of the promising strategies in recent years.

    Methods

    Expression of CTAs genes including MAGE A3, MAGE A4, MAGE C2 and NY-ESO-1 genes was detected with reverse transcription polymerase chain reaction (RT-PCR) in HCC tissues and corresponding adjacent non-cancerous tissues from 71 HCC patients.

    Results

    87.3% of HCC tumor tissue samples expressed at least 1 CTAs. HCC adjacent non-cancerous tissues did not express CTAs. 78.9% tumor tissue samples expressed MAGE-A3 mRNA, 33.8% samples expressed MAGE-A4 mRNA, 74.6% samples expressed MAGE-C2 mRNA and 14.1% samples expressed NY-ESO-1 mRNA. The expression of CTAs showed correlation with Ki67(r=0.27, P=0.02) and tumor stages (r=0.31, P=0.01), no correlation with clinical parameters such as age, gender, ALT, HLA-A2 positive, CA125, CA199, HBV or HCV infection and tumor size (P>0.05). The expression of MAGE-A3 showed correlation with the high expressions of CEA in serum (r=0.30, P=0.03), AFP in serum (r=0.26, P=0.03) and lymph node metastases (r=0.30, P=0.01).

    Conclusion

    Our findings demonstrate the cancer testis expression of CTAs genes show correlations with tumor stages and proliferation and may represent useful targets for tumor specific immunotherapy in HCC patients.

    View this table:

    Clinicopathological characteristics of the HCC patients